Literature DB >> 15722830

Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis.

David B Siepmann1, Alan Siegel, Petra J Lewis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722830     DOI: 10.1097/00003072-200503000-00015

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


× No keyword cloud information.
  6 in total

1.  Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.

Authors:  A Baehr; D Trog; M Oertel; S Welsch; K Kröger; O Grauer; U Haverkamp; H T Eich
Journal:  Strahlenther Onkol       Date:  2020-02-03       Impact factor: 3.621

2.  Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence.

Authors:  Manuel Gómez-Río; Antonio Rodríguez-Fernández; Carlos Ramos-Font; Escarlata López-Ramírez; José Manuel Llamas-Elvira
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-03       Impact factor: 9.236

3.  (11)C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas.

Authors:  Wanhu Li; Li Ma; Xiaoyue Wang; Jujie Sun; Suzhen Wang; Xudong Hu
Journal:  Tumour Biol       Date:  2014-09-03

4.  Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study.

Authors:  Fa-Ya Liang; Wei Sun; Ping Han; Xing Lu; Ying-Ni Lian; Xiao-Ming Huang
Journal:  Chin J Cancer       Date:  2012-01-09

5.  Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab.

Authors:  Naveed Wagle; Leia Nghiemphu; Albert Lai; Whitney Pope; Paul S Mischel; Timothy Cloughesy
Journal:  Pharmgenomics Pers Med       Date:  2010-06-09

6.  External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain.

Authors:  Peter Sminia; Ramona Mayer
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.